Controlling cellular distribution of drugs with permeability modifying moieties.
Journal
MedChemComm
ISSN: 2040-2511
Titre abrégé: Medchemcomm
Pays: England
ID NLM: 101531525
Informations de publication
Date de publication:
01 Jun 2019
01 Jun 2019
Historique:
received:
22
08
2018
accepted:
16
04
2019
entrez:
16
7
2019
pubmed:
16
7
2019
medline:
16
7
2019
Statut:
epublish
Résumé
Phenotypic screening provides compounds with very limited target cellular localization data. In order to select the most appropriate target identification methods, determining if a compound acts at the cell-surface or intracellularly can be very valuable. In addition, controlling cell-permeability of targeted therapeutics such as antibody-drug conjugates (ADCs) and targeted nanoparticle formulations can reduce toxicity from extracellular release of drug in undesired tissues or direct activity in bystander cells. By incorporating highly polar, anionic moieties
Identifiants
pubmed: 31303996
doi: 10.1039/c8md00412a
pii: c8md00412a
pmc: PMC6595965
doi:
Types de publication
Journal Article
Langues
eng
Pagination
974-984Références
Nat Biotechnol. 2005 Mar;23(3):329-36
pubmed: 15711537
Br J Pharmacol. 2006 Jan;147 Suppl 1:S127-35
pubmed: 16402096
N Engl J Med. 2006 Jun 15;354(24):2531-41
pubmed: 16775234
J Med Chem. 2006 Jun 29;49(13):3948-54
pubmed: 16789751
J Med Chem. 2007 Nov 1;50(22):5439-48
pubmed: 17918921
J Med Chem. 2007 Nov 15;50(23):5853-7
pubmed: 17956080
Endocrinology. 2008 Mar;149(3):1155-62
pubmed: 18079199
Nat Biotechnol. 2008 Jan;26(1):127-32
pubmed: 18183025
ChemMedChem. 2008 May;3(5):771-9
pubmed: 18247435
J Med Chem. 2008 Oct 23;51(20):6581-91
pubmed: 18800822
J Pharm Sci. 2009 Aug;98(8):2847-56
pubmed: 19408293
J Biomol Screen. 2009 Sep;14(8):924-35
pubmed: 19564447
Bioconjug Chem. 2010 May 19;21(5):903-10
pubmed: 20420372
Bioorg Med Chem Lett. 2010 Jun 1;20(11):3295-300
pubmed: 20457525
Nature. 2010 Dec 23;468(7327):1067-73
pubmed: 20871596
J Med Chem. 2011 Oct 13;54(19):6874-87
pubmed: 21870877
J Biol Chem. 1979 Apr 25;254(8):2923-7
pubmed: 218957
J Am Chem Soc. 2012 Feb 15;134(6):3001-14
pubmed: 22242683
J Am Chem Soc. 2012 Mar 7;134(9):3961-4
pubmed: 22352855
Nanoscale. 2012 Aug 21;4(16):5051-8
pubmed: 22767182
Mol Cell Proteomics. 2013 Jul;12(7):1764-79
pubmed: 23339905
Clin Pharmacol Ther. 2013 Apr;93(4):299-301
pubmed: 23511784
Mol Pharm. 2013 Jun 3;10(6):2467-78
pubmed: 23631740
Chem Biol. 2013 Nov 21;20(11):1307-8
pubmed: 24267273
Nat Biotechnol. 2014 Jan;32(1):92-6
pubmed: 24336317
Nat Commun. 2014 May 28;5:3946
pubmed: 24867710
J Biol Chem. 2015 Feb 20;290(8):4573-89
pubmed: 25552479
Cell. 2015 Jun 18;161(7):1668-80
pubmed: 26091042
Mol Cancer Res. 2015 Nov;13(11):1465-77
pubmed: 26217019
J Biomol Screen. 2016 Feb;21(2):201-11
pubmed: 26676096
J Health Econ. 2016 May;47:20-33
pubmed: 26928437
Mol Cell Oncol. 2015 Jun 10;3(1):e1052180
pubmed: 27308565
Nat Rev Drug Discov. 2017 Apr;16(4):285-296
pubmed: 28104905
Bioorg Med Chem Lett. 2017 May 15;27(10):2225-2233
pubmed: 28268136
Mol Cancer Ther. 2017 Jul;16(7):1236-1245
pubmed: 28468779
Bioorg Med Chem Lett. 2017 Aug 1;27(15):3317-3325
pubmed: 28610984
Nat Rev Drug Discov. 2017 Aug;16(8):531-543
pubmed: 28685762
J Am Chem Soc. 2017 Nov 22;139(46):16822-16829
pubmed: 29068676
Medchemcomm. 2017 Feb 21;8(4):789-795
pubmed: 30108797
Acta Pharm Suec. 1966 Sep;3(4):303-10
pubmed: 5975620
Pharmacol Rev. 1997 Sep;49(3):253-78
pubmed: 9311023